Cardioxyl primed for Phase IIa with $15 million funding
This article was originally published in Scrip
Executive Summary
Cardioxyl Pharmaceuticals, a clinical-stage US company developing novel therapeutics for cardiovascular disease based on its proprietary nitroxyl donor chemistry platform, has raised $15 million in venture financing to take its lead compound, CXL-1020, into a Phase IIa clinical trial.